iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects

Analyst Daina Graybosch of Leerink Partners reiterated a Hold rating on iTeos Therapeutics (ITOS – Research Report), boosting the price target to $11.00.

Daina Graybosch’s rating is based on the strategic decision by iTeos Therapeutics to wind down its operations, leveraging its strong cash reserves to maximize shareholder value. This decision comes as the market has not attributed significant value to iTeos’s current pipeline, making the reduction of cash burn a favorable move for the stock, which has seen a positive response compared to the broader market index.
Graybosch has valued iTeos’s cash at $11 per share through the end of the third quarter of 2025, factoring in the costs associated with winding down operations. The potential for additional proceeds from the company’s clinical or preclinical assets presents an upside to these estimates. Consequently, the Hold rating reflects a cautious approach, acknowledging the company’s current financial strategy while recognizing the limited immediate growth prospects from its existing pipeline.

In another report released yesterday, Wells Fargo also downgraded the stock to a Hold with a $12.00 price target.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ITOS in relation to earlier this year.